[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2011093828A3 - Formes posologiques solides comprenant du cefprozil - Google Patents

Formes posologiques solides comprenant du cefprozil Download PDF

Info

Publication number
WO2011093828A3
WO2011093828A3 PCT/TR2011/000032 TR2011000032W WO2011093828A3 WO 2011093828 A3 WO2011093828 A3 WO 2011093828A3 TR 2011000032 W TR2011000032 W TR 2011000032W WO 2011093828 A3 WO2011093828 A3 WO 2011093828A3
Authority
WO
WIPO (PCT)
Prior art keywords
cefprozil
dosage forms
solid dosage
solvates
hydrates
Prior art date
Application number
PCT/TR2011/000032
Other languages
English (en)
Other versions
WO2011093828A2 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093828A2 publication Critical patent/WO2011093828A2/fr
Publication of WO2011093828A3 publication Critical patent/WO2011093828A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes posologiques orales solides comprenant du cefprozil et/ou ses sels pharmaceutiquement acceptables, hydrates, solvates, esters, formes amorphes et formes cristallines et/ou une combinaison de ceux-ci.
PCT/TR2011/000032 2010-01-29 2011-01-28 Formes posologiques solides comprenant du cefprozil WO2011093828A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/00689 2010-01-29
TR2010/00689A TR201000689A1 (tr) 2010-01-29 2010-01-29 Sefprozil içeren katı dozaj formlar.

Publications (2)

Publication Number Publication Date
WO2011093828A2 WO2011093828A2 (fr) 2011-08-04
WO2011093828A3 true WO2011093828A3 (fr) 2012-02-23

Family

ID=44065360

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000032 WO2011093828A2 (fr) 2010-01-29 2011-01-28 Formes posologiques solides comprenant du cefprozil
PCT/TR2011/000036 WO2011093831A2 (fr) 2010-01-29 2011-01-31 Formulations effervescentes contenant du cefprosil comme principe actif

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000036 WO2011093831A2 (fr) 2010-01-29 2011-01-31 Formulations effervescentes contenant du cefprosil comme principe actif

Country Status (3)

Country Link
EP (1) EP2528593A2 (fr)
TR (1) TR201000689A1 (fr)
WO (2) WO2011093828A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102357086A (zh) * 2011-11-01 2012-02-22 上海理工大学 一种头孢丙烯口腔崩解片
WO2013109201A1 (fr) * 2012-01-18 2013-07-25 Mahmut Bilgic Compositions pharmaceutiques comprenant du cefprozil et de l'acide clavulanique
CN111658616B (zh) * 2020-05-22 2022-03-15 广州白云山医药集团股份有限公司白云山制药总厂 一种头孢丙烯干混悬剂及其制备方法
CN114886859A (zh) * 2022-06-09 2022-08-12 哈尔滨凯程制药有限公司 一种头孢丙烯颗粒剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1145711A1 (fr) * 2000-04-12 2001-10-17 Bristol-Myers Squibb Company Forme de dosage orale très fondante
CN101032489A (zh) * 2006-03-08 2007-09-12 上海秀新臣邦医药科技有限公司 头孢丙烯分散片及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520022A (en) 1983-01-28 1985-05-28 Bristol-Myers Company Substituted vinyl cephalosporins
CN100417383C (zh) * 2006-03-07 2008-09-10 中国药科大学 一种含有头孢克肟的泡腾片及制法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1145711A1 (fr) * 2000-04-12 2001-10-17 Bristol-Myers Squibb Company Forme de dosage orale très fondante
CN101032489A (zh) * 2006-03-08 2007-09-12 上海秀新臣邦医药科技有限公司 头孢丙烯分散片及其制备方法

Also Published As

Publication number Publication date
WO2011093831A3 (fr) 2012-02-23
TR201000689A1 (tr) 2011-08-22
WO2011093828A2 (fr) 2011-08-04
WO2011093831A2 (fr) 2011-08-04
EP2528593A2 (fr) 2012-12-05

Similar Documents

Publication Publication Date Title
EP2533783B8 (fr) COMPOSÉS ET PROCÉDÉS pour l' inhibition d' HDAC
WO2009114118A3 (fr) Compositions pharmaceutiques orales de buprénorphine et procédé d’utilisation
ZA201301329B (en) Novel compounds and compositions for the inhibition of nampt
ZA201206254B (en) Novel salts for the manufacture of pharmaceutical compositions
WO2011098582A3 (fr) Nouvelles formes de chlorhydrate d'ivabradine
WO2011093825A3 (fr) Formes posologiques effervescentes comprenant un antibiotique du groupe des céphalosporines
EP2627739B8 (fr) Dispositif pour la transformation d'un combustible
HK1221213A1 (zh) 作為消炎、免疫調節和抗增殖劑的新型化合物的新鈣鹽
EP2624815B8 (fr) Forme galénique à dissolution rapide de vaccin oral utilisant de l'amidon
PL2642993T3 (pl) Kompozycje rotygotyny lub farmaceutycznie dopuszczalnych soli rotygotyny
IL225371A0 (en) Focoxim conjugates are useful for the treatment of pathologies related to 90hsp
WO2012016683A3 (fr) Forme galénique orale de prégabaline
EP2532255A4 (fr) Produit de tabac oral
AU2012280198A8 (en) Darunavir combination formulations
WO2013055687A3 (fr) R(+)-n-formyl-propargyl-aminoindane
EP2454734B8 (fr) Dispositif pour l'enregistrement d'evenements
WO2011093828A3 (fr) Formes posologiques solides comprenant du cefprozil
WO2012074830A3 (fr) Formulation d'acide tranexamique à libération modifiée
SI2536396T1 (sl) Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
WO2011023954A3 (fr) Formes polymorphes de manidipine
PH12013500210A1 (en) Highly crystalline valsartan
ZA201200092B (en) Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
WO2011139253A3 (fr) Compositions pharmaceutiques comprenant du ceftibutène
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables
HUP1000565A2 (en) Process for the preparation of pharmaceutically active compound and intermediers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11713894

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11713894

Country of ref document: EP

Kind code of ref document: A2